Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $53 | $65 | $48 | $38 |
| % Growth | -18.5% | 37.5% | 24.2% | – |
| Cost of Goods Sold | $24 | $23 | $20 | $16 |
| Gross Profit | $29 | $43 | $28 | $22 |
| % Margin | 54.5% | 64.9% | 58.9% | 57.4% |
| R&D Expenses | $13 | $17 | $29 | $30 |
| G&A Expenses | $0 | $0 | -$14 | -$4 |
| SG&A Expenses | $12 | $15 | $12 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $25 | $17 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $32 | $41 | $42 |
| Operating Income | $4 | $10 | -$13 | -$20 |
| % Margin | 7.3% | 16% | -27.3% | -53.4% |
| Other Income/Exp. Net | $0 | -$2 | -$1 | -$7 |
| Pre-Tax Income | $4 | $9 | -$14 | -$28 |
| Tax Expense | $1 | $0 | $1 | $0 |
| Net Income | $3 | $8 | -$15 | -$28 |
| % Margin | 5.5% | 12.7% | -31.3% | -71.9% |
| EPS | 0.04 | 0.12 | -0.31 | -0.62 |
| % Growth | -66.3% | 138.7% | 50% | – |
| EPS Diluted | 0.037 | 0.1 | -0.31 | -0.62 |
| Weighted Avg Shares Out | 73 | 68 | 48 | 44 |
| Weighted Avg Shares Out Dil | 81 | 82 | 48 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $1 | $3 | $3 | $8 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $7 | $13 | -$11 | -$19 |
| % Margin | 12.2% | 19.8% | -22.6% | -49.4% |